Antimitotic drugs in cancer chemotherapy: Promises and pitfalls

被引：74

作者：

Marzo, Isabel ^{[1
]}

Naval, Javier ^{[1
]}

机构：

[1] Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, Zaragoza 50009, Spain

来源：

BIOCHEMICAL PHARMACOLOGY | 2013年 / 86卷 / 06期

关键词：

Mitosis; Cancer; Chemotherapy; DEPENDENT KINASE INHIBITOR; SPINDLE PROTEIN INHIBITOR; SMALL-MOLECULE INHIBITOR; RESISTANT PROSTATE-CANCER; PHASE-I; ANTITUMOR-ACTIVITY; AURORA KINASE; DOSE-ESCALATION; MITOTIC ARREST; CDK INHIBITOR;

D O I：

10.1016/j.bcp.2013.07.010

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cancer cells usually display higher proliferation rates than normal cells. Some currently used antitumor drugs, such as vinca alkaloids and taxanes, act by targeting microtubules and inhibiting mitosis. In the last years, different mitotic regulators have been proposed as drug target candidates for antitumor therapies. In particular, inhibitors of Cdks, Chks, Aurora kinase and Polo-like kinase have been synthesized and evaluated in vitro and in animal models and some of them have reached clinical trials. However, to date, none of these inhibitors has been still approved for use in chemotherapy regimes. We will discuss here the most recent preclinical information on those new antimitotic drugs, as well as the possible molecular bases underlying their lack of clinical efficiency. Also, advances in the identification of other mitosis-related targets will be also summarized. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：703 / 710

页数：8

共 89 条

[61] Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines [J].

Payton, Marc ;

Bush, Tammy L. ;

Chung, Grace ;

Ziegler, Beth ;

Eden, Patrick ;

McElroy, Patricia ;

Ross, Sandra ;

Cee, Victor J. ;

Deak, Holly L. ;

Hodous, Brian L. ;

Nguyen, Hanh Nho ;

Olivieri, Philip R. ;

Romero, Karina ;

Schenkel, Laurie B. ;

Bak, Annette ;

Stanton, Mary ;

Dussault, Isabelle ;

Patel, Vinod F. ;

Geuns-Meyer, Stephanie ;

Radinsky, Robert ;

Kendall, Richard L. .

CANCER RESEARCH, 2010, 70 (23) :9846-9854

[62] Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer [J].

Purcell, James W. ;

Davis, Jefferson ;

Reddy, Mamatha ;

Martin, Shamra ;

Samayoa, Kimberly ;

Vo, Hung ;

Thomsen, Karen ;

Bean, Peter ;

Kuo, Wen Lin ;

Ziyad, Safiyyah ;

Billig, Jessica ;

Feiler, Heidi S. ;

Gray, Joe W. ;

Wood, Kenneth W. ;

Cases, Sylvaine .

CLINICAL CANCER RESEARCH, 2010, 16 (02) :566-576

[63] MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts [J].

Rajeshkumar, N. V. ;

De Oliveira, Elizabeth ;

Ottenhof, Niki ;

Watters, James ;

Brooks, David ;

Demuth, Tim ;

Shumway, Stuart D. ;

Mizuarai, Shinji ;

Hirai, Hiroshi ;

Maitra, Anirban ;

Hidalgo, Manuel .

CLINICAL CANCER RESEARCH, 2011, 17 (09) :2799-2806

[64] Kinesins and cancer [J].

Rath, Oliver ;

Kozielski, Frank .

NATURE REVIEWS CANCER, 2012, 12 (08) :527-539

[65] Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells [J].

Rathos, Maggie J. ;

Khanwalkar, Harshal ;

Joshi, Kavita ;

Manohar, Sonal M. ;

Joshi, Kalpana S. .

BMC CANCER, 2013, 13

[66] VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells [J].

Ringer, Lymor ;

Sirajuddin, Paul ;

Heckler, Mary ;

Ghosh, Anup ;

Suprynowicz, Frank ;

Yenugonda, Venkata M. ;

Brown, Milton L. ;

Toretsky, Jeffrey A. ;

Uren, Aykut ;

Lee, YiChien ;

MacDonald, Tobey J. ;

Rodriguez, Olga ;

Glazer, Robert I. ;

Schlegel, Richard ;

Albanese, Chris .

CANCER BIOLOGY & THERAPY, 2011, 12 (09) :818-826

[67] Cyclin-dependent Kinase-1 (Cdk1)/Cyclin B1 Dictates Cell Fate after Mitotic Arrest via Phosphoregulation of Antiapoptotic Bcl-2 Proteins [J].

Sakurikar, Nandini ;

Eichhorn, Joshua M. ;

Chambers, Timothy C. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (46) :39193-39204

[68] A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours [J].

Schoffski, Patrick ;

Awada, Ahmad ;

Dumez, Herlinde ;

Gil, Thierry ;

Bartholomeus, Sylvie ;

Wolter, Pascal ;

Taton, Martine ;

Fritsch, Holger ;

Glomb, Patricia ;

Munzert, Gerd .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) :179-186

[69] Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours [J].

Schoffski, Patrick ;

Jones, Suzanne F. ;

Dumez, Herlinde ;

Infante, Jeffrey R. ;

Van Mieghem, Elke ;

Fowst, Camilla ;

Gerletti, Paola ;

Xu, Huiping ;

Jakubczak, John L. ;

English, Patricia A. ;

Pierce, Kristen J. ;

Burris, Howard A. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (15) :2256-2264

[70] MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel [J].

Shimomura, Toshiyasu ;

Hasako, Shinichi ;

Nakatsuru, Yoko ;

Mita, Takashi ;

Ichikawa, Koji ;

Kodera, Tsutomu ;

Sakai, Takumi ;

Nambu, Tadahiro ;

Miyamoto, Mayu ;

Takahashi, Ikuko ;

Miki, Satomi ;

Kawanishi, Nobuhiko ;

Ohkubo, Mitsuru ;

Kotani, Hidehito ;

Iwasawa, Yoshikazu .

MOLECULAR CANCER THERAPEUTICS, 2010, 9 (01) :157-166

← 1 2 3 4 5 6 7 8 9 →